NBI 34041
Alternative Names: SB 723620Latest Information Update: 11 Dec 2003
At a glance
- Originator Neurocrine Biosciences
- Developer GlaxoSmithKline
- Class Acenaphthenes; Antidepressants; Antispasmodics; Anxiolytics; Irritable bowel syndrome therapies
- Mechanism of Action Corticotropin-releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder
Most Recent Events
- 11 Dec 2003 Discontinued - Phase-I for Anxiety disorders in United Kingdom (unspecified route)
- 11 Dec 2003 Discontinued - Phase-I for Depression in United Kingdom (unspecified route)
- 11 Dec 2003 Discontinued - Phase-I for Irritable bowel syndrome in United Kingdom (unspecified route)